Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9168782rdf:typepubmed:Citationlld:pubmed
pubmed-article:9168782lifeskim:mentionsumls-concept:C0034493lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0234421lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0019010lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0021308lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0206146lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C1412251lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0443172lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:9168782lifeskim:mentionsumls-concept:C0718263lld:lifeskim
pubmed-article:9168782pubmed:issue6lld:pubmed
pubmed-article:9168782pubmed:dateCreated1997-6-23lld:pubmed
pubmed-article:9168782pubmed:abstractTextTo examine the cardioprotective role of A3 adenosine receptors during myocardial ischemia/reperfusion injury, we tested the effect of N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA), a potent and selective A3 adenosine receptor agonist, in models of myocardial stunning and infarction in chronically instrumented conscious rabbits. In phase I (studies of myocardial stunning), rabbits were subjected to six 4-minute coronary occlusions, each separated by 4-minute reperfusion periods, after which the recovery of systolic wall thickening was measured (ultrasonic crystals). In phase II (studies of myocardial infarction), rabbits were subjected to a 30-minute coronary occlusion followed by 3 days of reperfusion. In both phases, IB-MECA was administered as an intravenous bolus (100 micrograms/kg) 10 minutes before the first coronary occlusion. This dose of IB-MECA was determined in pilot studies to have no effect on heart rate, arterial blood pressure, or plasma histamine concentration in rabbits. In phase I, IB-MECA markedly improved the recovery of wall thickening after the six occlusion/reperfusion cycles, and this effect was sustained throughout the 5-hour observation period; the total deficit of wall thickening (a measure of the overall severity of myocardial stunning) was reduced by 68% (control, 129 +/- 16 arbitrary units, n = 7; IB-MECA, 41 +/- 6 arbitrary units, n = 6; P < .01). The protective effects of IB-MECA against stunning were completely blocked by pretreatment with the nonselective adenosine receptor antagonist 8-p-sulfophenyl theophylline or the specific protein kinase C inhibitor chelerythrine. In phase II, IB-MECA reduced myocardial infarct size by 61%; infarct size (tetrazolium staining) was 41 +/- 4% of the risk region in control animals (n = 8) and 16 +/- 6% in IB-MECA-treated animals (n = 8, P < .01). These results demonstrate that in conscious rabbits the A3 adenosine receptor agonist IB-MECA confers a powerful protection against both reversible (stunning) and irreversible (infarction) injury during acute myocardial ischemia and reperfusion by a protein kinase C-mediated pathway, suggesting that selective activation of A3 receptors is an effective means of protecting the ischemic myocardium without hemodynamic changes.lld:pubmed
pubmed-article:9168782pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:languageenglld:pubmed
pubmed-article:9168782pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:citationSubsetIMlld:pubmed
pubmed-article:9168782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9168782pubmed:statusMEDLINElld:pubmed
pubmed-article:9168782pubmed:monthJunlld:pubmed
pubmed-article:9168782pubmed:issn0009-7330lld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:MaldonadoCClld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:AuchampachJ...lld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:QinRRlld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:TangX LXLlld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:BolliRRlld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:RizviAAlld:pubmed
pubmed-article:9168782pubmed:authorpubmed-author:TeschnerSSlld:pubmed
pubmed-article:9168782pubmed:issnTypePrintlld:pubmed
pubmed-article:9168782pubmed:volume80lld:pubmed
pubmed-article:9168782pubmed:ownerNLMlld:pubmed
pubmed-article:9168782pubmed:authorsCompleteYlld:pubmed
pubmed-article:9168782pubmed:pagination800-9lld:pubmed
pubmed-article:9168782pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:meshHeadingpubmed-meshheading:9168782-...lld:pubmed
pubmed-article:9168782pubmed:year1997lld:pubmed
pubmed-article:9168782pubmed:articleTitleSelective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits.lld:pubmed
pubmed-article:9168782pubmed:affiliationDivision of Cardiology, University of Louisville, KY 40292, USA.lld:pubmed
pubmed-article:9168782pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9168782pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9168782pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9168782lld:pubmed